Replies to post #2298 on Biotech Values

[rstor1]

Alnylam

I was looking at them about a year ago, thinking of investing when they would go public. It seemed, at the time, that they were heavy into cross-licensing, rather than having a pipeline developed in-house. Even though they had a lot of scientific heavyweights on board, it seemed that they had not originated much IP.

Please take the above with a grain of salt, since the opinion is dated.

BTW - for all you ConjuFans - They initiated a PII combo with Metformin. Still holding on to my shares - planning to add when they come to the NAZ

Bob

[DewDiligence]

Merck aligns with Alnylam in AMD:

[This is quite a reversal of fortune for ALNY, which IPO’d one month ago and had to slash its IPO price by half just to get off. With Merck carrying the ball, ALNY becomes a serious competitor to Acuity Pharma among companies pursuing the RNAi approach to ophthalmic diseases.

ALNY is holding a CC today at 8:30 ET. I plan to listen.]

http://biz.yahoo.com/bw/040630/305261_1.html

>>
[Source: Merck & Co., Inc. & Alnylam]

Merck and Alnylam Establish New Strategic Alliance to Co-Develop and Co-Commercialize RNAi Therapeutics for Ocular Diseases

WHITEHOUSE STATION, N.J. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--June 30, 2004--Merck & Co., Inc. (NYSE: MRK) and Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY) announced today that they have entered into a new, multi-year collaboration to develop and commercialize RNAi therapeutics for ocular diseases. This collaboration, the second strategic alliance between Merck and Alnylam, will focus on age-related macular degeneration (AMD) and other ocular diseases caused by abnormal growth or leakage of small blood vessels in the eye. Alnylam's existing program to develop a Direct RNAi(TM) therapeutic for the treatment of AMD will be incorporated into the new collaboration.

Under the terms of the agreement, Alnylam will receive an initial cash payment from Merck and can receive additional cash payments upon the achievement of specified progress milestones. Cash payments to Alnylam could collectively total $19.5 million. In addition, Merck and Alnylam will jointly fund the development of, and share the profits from, any RNAi therapeutics for the United States market that result from the collaboration. Alnylam will also have the option to co-promote these RNAi therapeutics in the United States. Marketing and sales outside of the United States will be conducted by Merck, with Alnylam receiving royalties.

"This new alliance with Alnylam recognizes the potential of RNAi therapeutics for the treatment of AMD and other ocular diseases," said Peter S. Kim, Ph.D., president, Merck Research Laboratories. "Millions of patients each year suffer from severe loss of vision from these diseases and we are pleased to be working on a promising new approach with a leading company in the field."

In September 2003, Merck and Alnylam entered into the first major collaboration between a leading pharmaceutical company and an RNAi therapeutics company. In this ongoing alliance, Merck and Alnylam are collaborating to advance RNAi technology, which uses a natural biological mechanism to inhibit the expression of disease-causing genes, and to apply this technology to develop RNAi therapeutics that selectively target human diseases. The collaboration announced today is a new and additional alliance between the two companies.

"This new collaboration with Merck represents a major step forward in meeting our key objectives of developing important new drugs for patients and creating value for stockholders," commented John Maraganore, Ph.D., president and chief executive officer of Alnylam. "In particular, this opportunity to co-develop, co-promote and share profits from new ophthalmic drugs with Merck, which has a strong presence in the ophthalmology market, will greatly enhance the further development of Alnylam as an emerging leader in biotechnology."

About Age-related Macular Degeneration

The National Eye Institute estimates that more than 1.6 million adults over the age of 50 in the United States currently suffer from advanced age-related macular degeneration (AMD), a condition that causes severe deterioration of vision and may ultimately cause blindness. The macula is the central area of the retina that is responsible for sharpness of vision. Macular degeneration is a complex process involving the formation of fragile, newly-formed blood vessels behind the retina that tend to leak blood and fluid into the surrounding tissue. The presence of leaked fluids and new blood vessels behind the retina physically disrupts the integrity of the macula, resulting in blurring of central vision, and ultimately blindness.

Conference Call and Web Cast

Alnylam management will host a conference call and Web cast to discuss the collaboration at 8:30 a.m. ET on June 30. The conference call may be accessed by dialing [phone] (domestic callers) and [phone] (international). Please provide the passcode 23320527. A live Web cast will be available on the Alnylam website, www.alnylam.com, in the "Investors" section.

A replay of the conference call will be available beginning at 10:30 a.m. ET on June 30 through 10:30 a.m. ET on July 7 and may be accessed by dialing [phone] or [phone] and providing the passcode 17724186. An archived version of the Web cast will also be available on the Alnylam website for 30 days.

About Alnylam

Alnylam is a biopharmaceutical company seeking to develop and commercialize novel therapeutics based on RNA interference, or RNAi. Growing from its foundation as the world's first company focused on RNAi therapeutics, the company's leadership in the field of RNAi is supported by its preeminent founders and advisors and its strengths in fundamental patents, technology, and know-how that underlie the commercialization of RNAi therapeutics. Alnylam is developing a pipeline of RNAi products using Direct RNAi(TM) to treat ocular, central nervous system, and respiratory diseases and Systemic RNAi(TM) to treat a broad range of diseases, including oncologic, metabolic, and autoimmune diseases. The company's global headquarters are in Cambridge, Mass. For additional information, please visit http://www.alnylam.com.
<<